Does celiac disease influence survival in lymphoproliferative malignancy?

Jonas F. Ludvigsson, Benjamin Lebwohl, Alberto Rubio-Tapia, Joseph A Murray, Peter H R Green, Anders Ekbom, Fredrik Granath

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Celiac disease (CD) is associated with both lymphoproliferative malignancy (LPM) and increased death from LPM. Research suggests that co-existing autoimmune disease may influence survival in LPM. Through Cox regression we examined overall and cause-specific mortality in 316 individuals with CD+LPM versus 689 individuals with LPM only. CD was defined as having villous atrophy according to biopsy reports at any of Sweden's 28 pathology departments, and LPM as having a relevant disease code in the Swedish Cancer Register. During follow-up, there were 551 deaths (CD: n = 200; non-CD: n = 351). Individuals with CD+LPM were at an increased risk of death compared with LPM-only individuals [adjusted hazard ratio (aHR) = 1.23; 95 % confidence interval (CI) = 1.02-1.48]. However, this excess risk was only seen in the first year after LPM diagnosis (aHR = 1.76), with HRs decreasing to 1.09 in years 2-5 after LPM diagnosis and to 0.90 thereafter. Individuals with CD and non-Hodgkin lymphoma (NHL) were at a higher risk of any death as compared with NHL-only individuals (aHR = 1.23; 95 % CI = 0.97-1.56). This excess risk was due to a higher proportion of T cell lymphoma in CD patients. Stratifying for T- and B cell status, the HR for death in individuals with CD+NHL was 0.77 (95 % CI = 0.46-1.31). In conclusion, we found no evidence that co-existing CD influences survival in individuals with LPM. The increased mortality in the first year after LPM diagnosis is related to the predominance of T-NHL in CD individuals. Individuals with CD+LPM should be informed that their prognosis is similar to that of individuals with LPM only. However, this study had low statistical power to rule our excess mortality in patients with CD and certain LPM subtypes.

Original languageEnglish (US)
Pages (from-to)475-483
Number of pages9
JournalEuropean Journal of Epidemiology
Volume28
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Celiac Disease
Survival
Neoplasms
Non-Hodgkin's Lymphoma
Confidence Intervals
Mortality
T-Cell Lymphoma
Sweden
Autoimmune Diseases
Atrophy

Keywords

  • Cancer
  • Celiac
  • Coeliac
  • Death
  • Lymphoproliferative
  • Malignancy mortality

ASJC Scopus subject areas

  • Epidemiology

Cite this

Ludvigsson, J. F., Lebwohl, B., Rubio-Tapia, A., Murray, J. A., Green, P. H. R., Ekbom, A., & Granath, F. (2013). Does celiac disease influence survival in lymphoproliferative malignancy? European Journal of Epidemiology, 28(6), 475-483. https://doi.org/10.1007/s10654-013-9789-8

Does celiac disease influence survival in lymphoproliferative malignancy? / Ludvigsson, Jonas F.; Lebwohl, Benjamin; Rubio-Tapia, Alberto; Murray, Joseph A; Green, Peter H R; Ekbom, Anders; Granath, Fredrik.

In: European Journal of Epidemiology, Vol. 28, No. 6, 06.2013, p. 475-483.

Research output: Contribution to journalArticle

Ludvigsson, JF, Lebwohl, B, Rubio-Tapia, A, Murray, JA, Green, PHR, Ekbom, A & Granath, F 2013, 'Does celiac disease influence survival in lymphoproliferative malignancy?', European Journal of Epidemiology, vol. 28, no. 6, pp. 475-483. https://doi.org/10.1007/s10654-013-9789-8
Ludvigsson, Jonas F. ; Lebwohl, Benjamin ; Rubio-Tapia, Alberto ; Murray, Joseph A ; Green, Peter H R ; Ekbom, Anders ; Granath, Fredrik. / Does celiac disease influence survival in lymphoproliferative malignancy?. In: European Journal of Epidemiology. 2013 ; Vol. 28, No. 6. pp. 475-483.
@article{0c0199eeb2b94081bac7bce6990e44ed,
title = "Does celiac disease influence survival in lymphoproliferative malignancy?",
abstract = "Celiac disease (CD) is associated with both lymphoproliferative malignancy (LPM) and increased death from LPM. Research suggests that co-existing autoimmune disease may influence survival in LPM. Through Cox regression we examined overall and cause-specific mortality in 316 individuals with CD+LPM versus 689 individuals with LPM only. CD was defined as having villous atrophy according to biopsy reports at any of Sweden's 28 pathology departments, and LPM as having a relevant disease code in the Swedish Cancer Register. During follow-up, there were 551 deaths (CD: n = 200; non-CD: n = 351). Individuals with CD+LPM were at an increased risk of death compared with LPM-only individuals [adjusted hazard ratio (aHR) = 1.23; 95 {\%} confidence interval (CI) = 1.02-1.48]. However, this excess risk was only seen in the first year after LPM diagnosis (aHR = 1.76), with HRs decreasing to 1.09 in years 2-5 after LPM diagnosis and to 0.90 thereafter. Individuals with CD and non-Hodgkin lymphoma (NHL) were at a higher risk of any death as compared with NHL-only individuals (aHR = 1.23; 95 {\%} CI = 0.97-1.56). This excess risk was due to a higher proportion of T cell lymphoma in CD patients. Stratifying for T- and B cell status, the HR for death in individuals with CD+NHL was 0.77 (95 {\%} CI = 0.46-1.31). In conclusion, we found no evidence that co-existing CD influences survival in individuals with LPM. The increased mortality in the first year after LPM diagnosis is related to the predominance of T-NHL in CD individuals. Individuals with CD+LPM should be informed that their prognosis is similar to that of individuals with LPM only. However, this study had low statistical power to rule our excess mortality in patients with CD and certain LPM subtypes.",
keywords = "Cancer, Celiac, Coeliac, Death, Lymphoproliferative, Malignancy mortality",
author = "Ludvigsson, {Jonas F.} and Benjamin Lebwohl and Alberto Rubio-Tapia and Murray, {Joseph A} and Green, {Peter H R} and Anders Ekbom and Fredrik Granath",
year = "2013",
month = "6",
doi = "10.1007/s10654-013-9789-8",
language = "English (US)",
volume = "28",
pages = "475--483",
journal = "European Journal of Epidemiology",
issn = "0393-2990",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - Does celiac disease influence survival in lymphoproliferative malignancy?

AU - Ludvigsson, Jonas F.

AU - Lebwohl, Benjamin

AU - Rubio-Tapia, Alberto

AU - Murray, Joseph A

AU - Green, Peter H R

AU - Ekbom, Anders

AU - Granath, Fredrik

PY - 2013/6

Y1 - 2013/6

N2 - Celiac disease (CD) is associated with both lymphoproliferative malignancy (LPM) and increased death from LPM. Research suggests that co-existing autoimmune disease may influence survival in LPM. Through Cox regression we examined overall and cause-specific mortality in 316 individuals with CD+LPM versus 689 individuals with LPM only. CD was defined as having villous atrophy according to biopsy reports at any of Sweden's 28 pathology departments, and LPM as having a relevant disease code in the Swedish Cancer Register. During follow-up, there were 551 deaths (CD: n = 200; non-CD: n = 351). Individuals with CD+LPM were at an increased risk of death compared with LPM-only individuals [adjusted hazard ratio (aHR) = 1.23; 95 % confidence interval (CI) = 1.02-1.48]. However, this excess risk was only seen in the first year after LPM diagnosis (aHR = 1.76), with HRs decreasing to 1.09 in years 2-5 after LPM diagnosis and to 0.90 thereafter. Individuals with CD and non-Hodgkin lymphoma (NHL) were at a higher risk of any death as compared with NHL-only individuals (aHR = 1.23; 95 % CI = 0.97-1.56). This excess risk was due to a higher proportion of T cell lymphoma in CD patients. Stratifying for T- and B cell status, the HR for death in individuals with CD+NHL was 0.77 (95 % CI = 0.46-1.31). In conclusion, we found no evidence that co-existing CD influences survival in individuals with LPM. The increased mortality in the first year after LPM diagnosis is related to the predominance of T-NHL in CD individuals. Individuals with CD+LPM should be informed that their prognosis is similar to that of individuals with LPM only. However, this study had low statistical power to rule our excess mortality in patients with CD and certain LPM subtypes.

AB - Celiac disease (CD) is associated with both lymphoproliferative malignancy (LPM) and increased death from LPM. Research suggests that co-existing autoimmune disease may influence survival in LPM. Through Cox regression we examined overall and cause-specific mortality in 316 individuals with CD+LPM versus 689 individuals with LPM only. CD was defined as having villous atrophy according to biopsy reports at any of Sweden's 28 pathology departments, and LPM as having a relevant disease code in the Swedish Cancer Register. During follow-up, there were 551 deaths (CD: n = 200; non-CD: n = 351). Individuals with CD+LPM were at an increased risk of death compared with LPM-only individuals [adjusted hazard ratio (aHR) = 1.23; 95 % confidence interval (CI) = 1.02-1.48]. However, this excess risk was only seen in the first year after LPM diagnosis (aHR = 1.76), with HRs decreasing to 1.09 in years 2-5 after LPM diagnosis and to 0.90 thereafter. Individuals with CD and non-Hodgkin lymphoma (NHL) were at a higher risk of any death as compared with NHL-only individuals (aHR = 1.23; 95 % CI = 0.97-1.56). This excess risk was due to a higher proportion of T cell lymphoma in CD patients. Stratifying for T- and B cell status, the HR for death in individuals with CD+NHL was 0.77 (95 % CI = 0.46-1.31). In conclusion, we found no evidence that co-existing CD influences survival in individuals with LPM. The increased mortality in the first year after LPM diagnosis is related to the predominance of T-NHL in CD individuals. Individuals with CD+LPM should be informed that their prognosis is similar to that of individuals with LPM only. However, this study had low statistical power to rule our excess mortality in patients with CD and certain LPM subtypes.

KW - Cancer

KW - Celiac

KW - Coeliac

KW - Death

KW - Lymphoproliferative

KW - Malignancy mortality

UR - http://www.scopus.com/inward/record.url?scp=84879842190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879842190&partnerID=8YFLogxK

U2 - 10.1007/s10654-013-9789-8

DO - 10.1007/s10654-013-9789-8

M3 - Article

C2 - 23463575

AN - SCOPUS:84879842190

VL - 28

SP - 475

EP - 483

JO - European Journal of Epidemiology

JF - European Journal of Epidemiology

SN - 0393-2990

IS - 6

ER -